STADA Australia and BioQ Pharma Enter into Strategic Partnership to Commercialize Three Ready-to-Use Infusion Products

SYDNEY, Australia and SAN FRANCISCO, Aug. 23, 2017 -- STADA Pharmaceuticals Australia Pty Ltd (“STADA”) and BioQ Pharma Incorporated (“BioQ”), both specialty pharmaceutical companies, today announced a strategic agreement to commercialize three ready-to-use infusion pharmaceuticals in Australia and New Zealand.

STADA Pharmaceuticals Logo

The three-product collaboration between STADA and BioQ includes Ropivacaine ReadyfusOR, an opioid sparing post-surgical pain management therapy, as well as two other product candidates. Ropivacaine ReadyfusOR is a ready-to-use, single use infusion product, which is pre-filled by the manufacturer with 0.2% Ropivacaine. It is a self-contained drug and administration system for delivery at the point of care, activated by a single touch. Ropivacaine ReadyfusOR was recently approved by the Therapeutic Goods Administration (“TGA”).

“We are very excited about this new partnership and look forward to working with the STADA team to advance our mutual commercial ambitions in Australia and New Zealand,” said Josh Kriesel, President and CEO of BioQ Pharma.

Gary Clark, Managing Director of STADA Australia, commented, “STADA welcomes the opportunity to partner with BioQ to introduce these innovative, self-contained infusion pharmaceuticals to the Australian and New Zealand markets. The addition of these exciting products to our portfolio will enhance our reputation as a provider of quality healthcare, leading to improved patient outcomes.”

About STADA Pharmaceuticals Australia Pty Ltd
STADA Pharmaceuticals Australia, a wholly-owned subsidiary of STADA Arzneimittel AG, was established in 2012 and launched its branded product MOVAPO® for the treatment of Parkinsons Disease in Australia and New Zealand in 2016. STADA Australia’s portfolio expansion activities will lead to the launch of a number of new branded products in the coming years.

STADA Arzneimittel AG is a publicly-listed company with headquarters in Bad Vilbel, Germany. STADA consistently focuses on a multi-pillar strategy of generics and branded products (OTC) with an increasingly international market orientation. Worldwide, STADA is represented in more than 30 countries with more than 50 subsidiaries. In financial year 2016, STADA achieved adjusted Group sales of Euro 2,167.2 million. As of December 31, 2016, STADA employed about 10,900 people worldwide.

About BioQ Pharma
BioQ Pharma Incorporated is a privately held specialty pharmaceutical company focused on developing and commercializing ready-to-use infusible pharmaceuticals. The Company's infusion platform is intended to address some of the most pressing unmet needs in drug infusion today: cost, medication error, sterility, efficiency, and patient quality of life. BioQ Pharma's vision is to set a new standard of care in the presentation and administration of infusible pharmaceuticals via the Company's proprietary unit-dose infusion systems that can be deployed quickly and conveniently at the point of care with one touch. The Company is ISO13485 certified. BioQ Pharma's commercial collaborators and strategic partners include Novartis' Sandoz unit, Cipla, Lee's Pharm, Lunatus, Galen Limited, STADA Australia, Pharma Mart, and West Pharmaceutical Services.

Company Contact Information:

Gary Clark
STADA Pharmaceuticals Australia 
Managing Director
+61 2 9965 7288

Josh Kriesel
BioQ Pharma
President and CEO
+1-415-336-6496

Ron Pauli
BioQ Pharma
Chief Financial Officer
+1-415-889-7707

Walter Cleymans
BioQ Pharma
Chief Commercial Officer 
Phone: +32 474 (053) 253

Media:
Stephanie Carrington
Integrated Corporate Relations, Inc. (ICR)
+1-646-277-1282